LAVA Therapeutics (LVTX) Earnings Date, Estimates & Call Transcripts → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free LVTX Stock Alerts $3.11 +0.03 (+0.97%) (As of 04:00 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateJun. 13EstimatedActual EPS (Mar. 20) -$0.24 Missed By -$0.40 Consensus EPS (Mar. 20) $0.16 Get LAVA Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for LVTX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueLVTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LVTX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceProof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…Go here now for full story. LAVA Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243($1.35)($0.39)($0.72)Q2 20243($1.59)($0.39)($0.80)Q3 20243($1.57)($0.40)($0.80)Q4 20243($0.83)($0.40)($0.55)FY 202412($5.34)($1.58)($2.86)LVTX Earnings Date and InformationLAVA Therapeutics last posted its quarterly earnings results on March 20th, 2024. The reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by $0.40. The firm earned $0.35 million during the quarter, compared to analyst estimates of $25 million. LAVA Therapeutics has generated ($1.59) earnings per share over the last year (($1.59) diluted earnings per share). Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.77) per share. LAVA Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 13th, 2024 based off prior year's report dates.Read More LAVA Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 6/13/2024Estimated)------- 3/20/2024Q4 2023$0.16($0.24)($0.40)($0.24)$25.00 million$0.35 million11/16/2023Q3 2023($0.49)($0.34)+$0.15($0.34)-$0.05 million8/22/2023Q2 2023($0.50)($0.48)+$0.02($0.48)$2.50 million$5.14 million6/8/2023Q1 2023($0.49)($0.53)($0.04)($0.53)-$1.22 million4/11/2023Q4 2022-($0.57)($0.57)($0.57)-$2.64 million11/16/2022Q3 2022($0.07)$0.04+$0.11$0.04$25.00 million$15.26 million Get the Latest News and Ratings for LVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/13/2022Q2 2022($0.61)($0.31)+$0.30($0.31)$1.00 million$0.47 million5/17/2022Q1 2022($0.95)($0.41)+$0.54($0.41)-$1.00 million3/24/2022Q4 2021($0.38)($0.38)-($0.38)$1.32 million$1.00 million11/14/2021Q3 2021($0.28)($0.27)+$0.01($0.27)-$2.10 million8/15/2021Q2 2021($0.24)($0.28)($0.04)($0.28)-$1.08 million5/20/2021Q1 2021($0.27)($12.28)($12.01)($12.28)-$1.11 million LAVA Therapeutics Earnings - Frequently Asked Questions When is LAVA Therapeutics's earnings date? LAVA Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 13th, 2024 based off last year's report dates. Learn more on LVTX's earnings history. Did LAVA Therapeutics beat their earnings estimates last quarter? In the previous quarter, LAVA Therapeutics (NASDAQ:LVTX) missed the analysts' consensus estimate of $0.16 by $0.40 with a reported earnings per share (EPS) of ($0.24). Learn more on analysts' earnings estimate vs. LVTX's actual earnings. How much revenue does LAVA Therapeutics generate each year? LAVA Therapeutics (NASDAQ:LVTX) has a recorded annual revenue of $6.77 million. How much profit does LAVA Therapeutics generate each year? LAVA Therapeutics (NASDAQ:LVTX) has a recorded net income of -$41.97 million. LVTX has generated -$1.59 earnings per share over the last four quarters. What is LAVA Therapeutics's EPS forecast for next year? LAVA Therapeutics's earnings are expected to decrease from ($1.41) per share to ($1.77) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Context Therapeutics Earnings Date Grifols Earnings Date Mainz Biomed Earnings Date Pharvaris Earnings Date Shattuck Labs Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NASDAQ:LVTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
